Identification of p53 mutations in archival prostate tumors

Sensitivity of an optimized single-strand conformational polymorphism (SSCP) assay

Xu Bao Shi, Sara M. Bodner, Ralph W deVere White, Paul H. Gumerlock

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

To correlate molecular changes with clinical information in prostate tissue, it is necessary to have accurate methods for screening for mutations in clinically available specimens. We have refined the polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) analysis for detection of p53 mutations in routine pathology specimens. These improvements help overcome technical barriers that interfere with SSCP analysis of archival tissues when only small amounts of poorly preserved formalin-fixed DNA are available. Furthermore, prostate samples are heterogeneous in containing tumor, normal tissue, and hyperplastic tissue. To address the first issue, the method included an initial selection of PCR products using exonuclease I, followed by a second-step selection using nested PCR. This step ensures adequate amplification of the target sequence while minimizing artifactual products that could otherwise interfere with mutation analysis. For the second issue, in addition to morphologic selection of appropriate tissue areas, we improved the sensitivity of detection of mutations by using restriction enzyme digestion of products prior to SSCP analysis. Detection of mutations in heterogeneous tissue was evaluated by determining the minimal detectable mutant allele frequencies in exons 4, 5, 6, 7, 8-9, and 10 by using mixtures of known mutant and wild-type cell lines, which were found to be 17.6, 9.1, 12.5, 8.1, 14.0, and 14.3%, respectively. To determine the utility of this method when used on heterogeneous clinical samples, we performed a study of 19 archival prostate specimens (14 primary prostate cancers, three benign prostatic hyperplasia and two metastases) and detected abnormally migrating products in six of the prostate cancer specimens (four primaries and two metastases). In five of these samples, there was sufficient DNA to perform sequencing, which disclosed single-base change mutations in all five samples.

Original languageEnglish (US)
Pages (from-to)271-278
Number of pages8
JournalDiagnostic Molecular Pathology
Volume5
Issue number4
DOIs
StatePublished - 1996

Fingerprint

Prostate
Mutation
Neoplasms
Polymerase Chain Reaction
Prostatic Neoplasms
Neoplasm Metastasis
DNA
Prostatic Hyperplasia
Gene Frequency
Formaldehyde
Digestion
Exons
Pathology
Cell Line
Enzymes

Keywords

  • Archival tissue
  • p53
  • PCR
  • Prostate cancer
  • SSCP

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Identification of p53 mutations in archival prostate tumors : Sensitivity of an optimized single-strand conformational polymorphism (SSCP) assay. / Shi, Xu Bao; Bodner, Sara M.; deVere White, Ralph W; Gumerlock, Paul H.

In: Diagnostic Molecular Pathology, Vol. 5, No. 4, 1996, p. 271-278.

Research output: Contribution to journalArticle

@article{2e07d741a89c4701bce23c3ce439085e,
title = "Identification of p53 mutations in archival prostate tumors: Sensitivity of an optimized single-strand conformational polymorphism (SSCP) assay",
abstract = "To correlate molecular changes with clinical information in prostate tissue, it is necessary to have accurate methods for screening for mutations in clinically available specimens. We have refined the polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) analysis for detection of p53 mutations in routine pathology specimens. These improvements help overcome technical barriers that interfere with SSCP analysis of archival tissues when only small amounts of poorly preserved formalin-fixed DNA are available. Furthermore, prostate samples are heterogeneous in containing tumor, normal tissue, and hyperplastic tissue. To address the first issue, the method included an initial selection of PCR products using exonuclease I, followed by a second-step selection using nested PCR. This step ensures adequate amplification of the target sequence while minimizing artifactual products that could otherwise interfere with mutation analysis. For the second issue, in addition to morphologic selection of appropriate tissue areas, we improved the sensitivity of detection of mutations by using restriction enzyme digestion of products prior to SSCP analysis. Detection of mutations in heterogeneous tissue was evaluated by determining the minimal detectable mutant allele frequencies in exons 4, 5, 6, 7, 8-9, and 10 by using mixtures of known mutant and wild-type cell lines, which were found to be 17.6, 9.1, 12.5, 8.1, 14.0, and 14.3{\%}, respectively. To determine the utility of this method when used on heterogeneous clinical samples, we performed a study of 19 archival prostate specimens (14 primary prostate cancers, three benign prostatic hyperplasia and two metastases) and detected abnormally migrating products in six of the prostate cancer specimens (four primaries and two metastases). In five of these samples, there was sufficient DNA to perform sequencing, which disclosed single-base change mutations in all five samples.",
keywords = "Archival tissue, p53, PCR, Prostate cancer, SSCP",
author = "Shi, {Xu Bao} and Bodner, {Sara M.} and {deVere White}, {Ralph W} and Gumerlock, {Paul H.}",
year = "1996",
doi = "10.1097/00019606-199612000-00008",
language = "English (US)",
volume = "5",
pages = "271--278",
journal = "Diagnostic Molecular Pathology",
issn = "1052-9551",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Identification of p53 mutations in archival prostate tumors

T2 - Sensitivity of an optimized single-strand conformational polymorphism (SSCP) assay

AU - Shi, Xu Bao

AU - Bodner, Sara M.

AU - deVere White, Ralph W

AU - Gumerlock, Paul H.

PY - 1996

Y1 - 1996

N2 - To correlate molecular changes with clinical information in prostate tissue, it is necessary to have accurate methods for screening for mutations in clinically available specimens. We have refined the polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) analysis for detection of p53 mutations in routine pathology specimens. These improvements help overcome technical barriers that interfere with SSCP analysis of archival tissues when only small amounts of poorly preserved formalin-fixed DNA are available. Furthermore, prostate samples are heterogeneous in containing tumor, normal tissue, and hyperplastic tissue. To address the first issue, the method included an initial selection of PCR products using exonuclease I, followed by a second-step selection using nested PCR. This step ensures adequate amplification of the target sequence while minimizing artifactual products that could otherwise interfere with mutation analysis. For the second issue, in addition to morphologic selection of appropriate tissue areas, we improved the sensitivity of detection of mutations by using restriction enzyme digestion of products prior to SSCP analysis. Detection of mutations in heterogeneous tissue was evaluated by determining the minimal detectable mutant allele frequencies in exons 4, 5, 6, 7, 8-9, and 10 by using mixtures of known mutant and wild-type cell lines, which were found to be 17.6, 9.1, 12.5, 8.1, 14.0, and 14.3%, respectively. To determine the utility of this method when used on heterogeneous clinical samples, we performed a study of 19 archival prostate specimens (14 primary prostate cancers, three benign prostatic hyperplasia and two metastases) and detected abnormally migrating products in six of the prostate cancer specimens (four primaries and two metastases). In five of these samples, there was sufficient DNA to perform sequencing, which disclosed single-base change mutations in all five samples.

AB - To correlate molecular changes with clinical information in prostate tissue, it is necessary to have accurate methods for screening for mutations in clinically available specimens. We have refined the polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) analysis for detection of p53 mutations in routine pathology specimens. These improvements help overcome technical barriers that interfere with SSCP analysis of archival tissues when only small amounts of poorly preserved formalin-fixed DNA are available. Furthermore, prostate samples are heterogeneous in containing tumor, normal tissue, and hyperplastic tissue. To address the first issue, the method included an initial selection of PCR products using exonuclease I, followed by a second-step selection using nested PCR. This step ensures adequate amplification of the target sequence while minimizing artifactual products that could otherwise interfere with mutation analysis. For the second issue, in addition to morphologic selection of appropriate tissue areas, we improved the sensitivity of detection of mutations by using restriction enzyme digestion of products prior to SSCP analysis. Detection of mutations in heterogeneous tissue was evaluated by determining the minimal detectable mutant allele frequencies in exons 4, 5, 6, 7, 8-9, and 10 by using mixtures of known mutant and wild-type cell lines, which were found to be 17.6, 9.1, 12.5, 8.1, 14.0, and 14.3%, respectively. To determine the utility of this method when used on heterogeneous clinical samples, we performed a study of 19 archival prostate specimens (14 primary prostate cancers, three benign prostatic hyperplasia and two metastases) and detected abnormally migrating products in six of the prostate cancer specimens (four primaries and two metastases). In five of these samples, there was sufficient DNA to perform sequencing, which disclosed single-base change mutations in all five samples.

KW - Archival tissue

KW - p53

KW - PCR

KW - Prostate cancer

KW - SSCP

UR - http://www.scopus.com/inward/record.url?scp=0029856286&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029856286&partnerID=8YFLogxK

U2 - 10.1097/00019606-199612000-00008

DO - 10.1097/00019606-199612000-00008

M3 - Article

VL - 5

SP - 271

EP - 278

JO - Diagnostic Molecular Pathology

JF - Diagnostic Molecular Pathology

SN - 1052-9551

IS - 4

ER -